bioMérieux 2016 Annual Report

16 May, 2017

A world leader in the field of in vitro diagnostics for more than 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors. In 2016, revenues reached €2,103 million with 90% of international sales. 

2016 was an outstanding year for bioMérieux. We achieved excellent results in a balanced performance across all areas of the business. Today bioMérieux’s footprint places us among the industry elite. With nearly 10,000 employees and revenues up 9.6% to reach more than €2 billion, the Company is the world leader in microbiology, in both infectious disease diagnostics and industrial quality control. These remarkable results once again demonstrate the relevance of a long-term strategy that we are able to successfully implement in over 150 countries through our extremely solid network.

Innovation was this year’s guiding principle, taking the form of successful launches across all product lines: high medical value tests that respond to major public health challenges, and innovative solutions to support manufacturers in protecting the health of consumers while maintaining efficient production processes. This annual report highlights these achievements.

Our capacity for innovation is the result of a long-term vision that was essential in enabling us to carry out ambitious R&D programs in-house while forming high-level research partnerships with the international medical and scientific community.

Our capacity for innovation is also linked to our entrepreneurial approach to targeted acquisitions through which we gain technologies that are critical to the diagnostics of tomorrow.

With the successful integration of BioFire and, over the past two years, the growing prominence of its syndromic infectious disease diagnostic solutions, we are pioneers in a cutting-edge field for rapid, optimized patient care.

In addition, we enjoy a stronger position in the now-essential field of data analytics following the early-2016 acquisition of Applied Maths, which models biological complexity to enhance the understanding of diseases and inform physicians.

Lastly, on the industry side, the acquisition of the company Hyglos, an expert in the development of recombinant proteins for the detection of endotoxins, has further broadened our expertise in quality control of pharmaceutical products.

We are witnessing the explosion of medico-scientific and technological knowledge as well as the arrival, in our business, of new stakeholders coming from beyond the healthcare sector.

Against this backdrop of fast-paced, constant change, bioMérieux enjoys the benefit of its diverse, world- class competencies. We mobilize our multidisciplinary R&D teams comprising more than 1,500 collaborators, including biologists and physicians as well as engineers and biomathematicians. We make use of high-potential technologies that, when combined with our century- old medical culture, represent a unique heritage and a singular advantage in understanding increasingly complex scientific challenges.

It is said that the medicine of the future will revolve around “four Ps”: Preventive, Predictive, Personalized and Participative. Without a doubt, diagnostics will have a key role to play in this new paradigm, and we are making every effort to further strengthen its medical value.Sustained by our sound innovation strategy, the relevance of our acquisitions, the solidity of our bioindustrial fundamentals and the quality of our international network, we are poised to be a major player in the medicine of tomorrow.

bioMérieux has a clear vision for the future, and today we have the means to support our ambitions. Under the leadership of Alexander Mérieux, the Company will be ready to evolve and to serve global public health even more closely.

Jean-Luc Belingard
Download our Annual Report for more information. 


Diagnostics is power